Warning: Undefined array key "mm" in /www/wwwroot/www.ai-bt.com/si.php on line 10 Deprecated: trim(): Passing null to parameter #1 ($string) of type string is deprecated in /www/wwwroot/www.ai-bt.com/si.php on line 10 Susceptibility testing of Mycobacterium avium complex isolates.

× No keyword cloud information.

104 in total

Review 1. Mycobacterium avium complex infection in the acquired immunodeficiency syndrome.

Authors: C R Horsburgh
Journal: N Engl J Med Date: 1991-05-09 Impact factor: 91.245

2. Individualized therapy versus standard regimens in the treatment of Mycobacterium avium infections.

Authors: L B Heifets; M D Iseman
Journal: Am Rev Respir Dis Date: 1991-07

3. Choice of antimicrobial agents for M. avium disease based on quantitative tests of drug susceptibility.

Authors: L B Heifets; M D Iseman
Journal: N Engl J Med Date: 1990-08-09 Impact factor: 91.245

4. Quadruple-drug therapy for Mycobacterium avium-intracellulare bacteremia in AIDS patients.

Authors: J Hoy; A Mijch; M Sandland; L Grayson; R Lucas; B Dwyer
Journal: J Infect Dis Date: 1990-04 Impact factor: 5.226

5. Cervicofacial mycobacterial adenitis in children: endemic to San Diego?

Authors: S M Pransky; B K Reisman; D B Kearns; A B Seid; D L Collins; H F Krous
Journal: Laryngoscope Date: 1990-09 Impact factor: 3.325

6. Comparison of bactericidal activities of streptomycin, amikacin, kanamycin, and capreomycin against Mycobacterium avium and M. tuberculosis.

Authors: L Heifets; P Lindholm-Levy
Journal: Antimicrob Agents Chemother Date: 1989-08 Impact factor: 5.191

7. Treatment of disseminated Mycobacterium avium complex infection in AIDS with amikacin, ethambutol, rifampin, and ciprofloxacin. California Collaborative Treatment Group.

Authors: J Chiu; J Nussbaum; S Bozzette; J G Tilles; L S Young; J Leedom; P N Heseltine; J A McCutchan
Journal: Ann Intern Med Date: 1990-09-01 Impact factor: 25.391

8. Successful treatment of acquired immunodeficiency syndrome-related Mycobacterium avium complex disease with a multiple drug regimen including amikacin.

Authors: C A Benson; H A Kessler; J C Pottage; G M Trenholme
Journal: Arch Intern Med Date: 1991-03

9. Mycobacterium avium complex pulmonary disease. Incidence, presentation, and response to therapy in a community setting.

Authors: J M Reich; R E Johnson
Journal: Am Rev Respir Dis Date: 1991-06

10. Bactericidal activity in vitro of various rifamycins against Mycobacterium avium and Mycobacterium tuberculosis.

Authors: L B Heifets; P J Lindholm-Levy; M A Flory
Journal: Am Rev Respir Dis Date: 1990-03

13 in total

1. Management of opportunist mycobacterial infections: Joint Tuberculosis Committee Guidelines 1999. Subcommittee of the Joint Tuberculosis Committee of the British Thoracic Society.

Authors:
Journal: Thorax Date: 2000-03 Impact factor: 9.139

2. Biomarkers of HIV Immune Reconstitution Inflammatory Syndrome.

Authors: Shuli Bonham; David B Meya; Paul R Bohjanen; David R Boulware
Journal: Biomark Med Date: 2008 Impact factor: 2.851

3. Bactericidal activities of the pyrrole derivative BM212 against multidrug-resistant and intramacrophagic Mycobacterium tuberculosis strains.

Authors: D Deidda; G Lampis; R Fioravanti; M Biava; G C Porretta; S Zanetti; R Pompei
Journal: Antimicrob Agents Chemother Date: 1998-11 Impact factor: 5.191

4. Activities of isoniazid alone and in combination with other drugs against Mycobacterium avium infection in beige mice.

Authors: L Fattorini; Y Xiao; M Mattei; Y Li; E Iona; M L Ricci; O F Thoresen; R Creti; G Orefici
Journal: Antimicrob Agents Chemother Date: 1998-03 Impact factor: 5.191

5. Clinical and prognostic importance of serotyping Mycobacterium avium-Mycobacterium intracellulare complex isolates in human immunodeficiency virus-negative patients.

Authors: Ryoji Maekura; Yoshinari Okuda; Atsusi Hirotani; Seigo Kitada; Touru Hiraga; Kenji Yoshimura; Ikuya Yano; Kazuo Kobayashi; Masami Ito
Journal: J Clin Microbiol Date: 2005-07 Impact factor: 5.948

Review 6. The role of advanced generation macrolides in the prophylaxis and treatment of Mycobacterium avium complex (MAC) infections.

Authors: G W Amsden; C A Peloquin; S E Berning
Journal: Drugs Date: 1997-07 Impact factor: 9.546

7. Recurrent mycobacterial infections in a patient with IL-12 deficiency.

Authors: Matthew Buckland; Roshanara Ali; Graham Bothamley; David Lammas; Rainer Doffinger; Hilary Longhurst
Journal: BMJ Case Rep Date: 2009-12-01

8. Multisite reproducibility of results obtained by two broth dilution methods for susceptibility testing of Mycobacterium avium complex.

Authors: Gail L Woods; Natalie Williams-Bouyer; Richard J Wallace; Barbara A Brown-Elliott; Frank G Witebsky; Patricia S Conville; Marianne Plaunt; Geraldine Hall; Priscilla Aralar; Clark Inderlied
Journal: J Clin Microbiol Date: 2003-02 Impact factor: 5.948

9. Mutational analysis of cell wall biosynthesis in Mycobacterium avium.

Authors: Jean-Pierre Laurent; Kirsten Hauge; Kellie Burnside; Gerard Cangelosi
Journal: J Bacteriol Date: 2003-08 Impact factor: 3.490

10. Interaction of antimycobacterial drugs with the anti-Mycobacterium avium complex effects of antimicrobial effectors, reactive oxygen intermediates, reactive nitrogen intermediates, and free fatty acids produced by macrophages.

Authors: Keisuke Sano; Haruaki Tomioka; Katsumasa Sato; Chiaki Sano; Hideyuki Kawauchi; Shanshan Cai; Toshiaki Shimizu
Journal: Antimicrob Agents Chemother Date: 2004-06 Impact factor: 5.191